This document summarizes Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. It discusses the disease pathogenesis, symptoms in four stages, incidence, diagnosis, management, and multidisciplinary care. Management includes corticosteroids to prolong ambulation, physical therapy, bracing, spinal surgery, cardiac and respiratory care including ventilation, nutrition support, and psychosocial interventions. DMD significantly reduces life expectancy but improvements in clinical care have increased average survival into the late 20s or beyond.
This presentation contains detailed knowledge about Down's Syndrome its types, clinical presentation, diagnosis, medical and physio therapeutic management of the condition.
Down syndrome is a condition in which a person has an extra chromosome. Chromosomes are small “packages” of genes in the body. They determine how a baby’s body forms and functions as it grows during pregnancy and after birth. Typically, a baby is born with 46 chromosomes. Babies with Down syndrome have an extra copy of one of these chromosomes, chromosome 21. A medical term for having an extra copy of a chromosome is ‘trisomy.’ Down syndrome is also referred to as Trisomy 21. This extra copy changes how the baby’s body and brain develop, which can cause both mental and physical challenges for the baby.
This presentation contains detailed knowledge about Down's Syndrome its types, clinical presentation, diagnosis, medical and physio therapeutic management of the condition.
Down syndrome is a condition in which a person has an extra chromosome. Chromosomes are small “packages” of genes in the body. They determine how a baby’s body forms and functions as it grows during pregnancy and after birth. Typically, a baby is born with 46 chromosomes. Babies with Down syndrome have an extra copy of one of these chromosomes, chromosome 21. A medical term for having an extra copy of a chromosome is ‘trisomy.’ Down syndrome is also referred to as Trisomy 21. This extra copy changes how the baby’s body and brain develop, which can cause both mental and physical challenges for the baby.
This ppt describes various movement disorders found commonly in elderly persons. It also describes hyper and hypokinetic disorder categorization with cause and pathophysiology of movement disorders.
achondroplasia is genetic disorder that results in dwarfism
problem is not in forming cartilage but in converting it to bone.
This disorder usually results in the following: An average-size trunk; Short arms and legs, with particularly short upper arms and upper legs; Short fingers.
Mutation in FGFR3 on chromosome 4 is responsible for achondroplasia.
This ppt describes various movement disorders found commonly in elderly persons. It also describes hyper and hypokinetic disorder categorization with cause and pathophysiology of movement disorders.
achondroplasia is genetic disorder that results in dwarfism
problem is not in forming cartilage but in converting it to bone.
This disorder usually results in the following: An average-size trunk; Short arms and legs, with particularly short upper arms and upper legs; Short fingers.
Mutation in FGFR3 on chromosome 4 is responsible for achondroplasia.
Cardiopulmonary Conditions Instructions(Must be included in pape.docxannandleola
Cardiopulmonary Conditions Instructions
(Must be included in paper and discussed in presentation)
1. What population is this condition typically found in?
2. How does the condition typically occur? What is the etiology?
3. What anatomical structures are involved?
4. What medical interventions are required?
5. What precautions or contraindications must the PTA be aware of during the patient’s medical treatment and/or during recovery?
6. What is the typical time frame for patient full recovery OR how long following medical intervention until the patient is considered able to return to full functional abilities (or return to PLOF).
7. What types of PT interventions are typically used to treat the condition during the:
a. acute phase
b. functional phase
8. Are there any recommended interventions that do not fall under the PTA’s scope of work?
9. Create an example daily treatment plan for the patient 3 weeks following injury/medical intervention based on information found during your research.
Running head: AN EXPLORE OF SARCOIDOSIS: MANAGING SARCOIDOSIS CONDITION
AN EXPLORE ON SARCOIDOSIS 2
AN EXPLORE ON SARCOIDOSIS
Student’s Name
Institutional Affiliation
An Explore on Sarcoidosis
Medical experts have discovered that sarcoidosis is a sequential ailment whose cause remains a mystery yet it presents varied and numerous forms of conditions, consequences, severity, and needs for medical attention especially treatments (Liu et al., 2014). Bearing in mind that sarcoidosis ailment associated with the development of tiny chains of inflammatory cells mainly in the lungs and lymph nodes as well as eyes and skin, the presentation of this condition could be typical or in many cases, they remain non-specific hence could mislead the diagnostic outcomes. The most significant case which could present this condition is the one with the forefront of pulmonary manifestations (Alicia, 2014). Consequently, the diagnosis depends on three common criteria which are not clinically common.
The Rates of Morbidity courtesy of Sarcoidosis
Scientific researches affiliated to the Sarcoidosis deaths in the States: 1999 to 2016 courtesy of the journal Respiratory Medicine explored that, America loses about 16,665 people through sarcoidosis. The data also revealed that the mortality rates had increased from 2.1 to 3 per 1 million persons in 1999 to 2016 respectively (Blankstein et al., 2014). These rates seemed to have increased from 2.1 to 3.1 from 1999 to 2002 and remained stable in the progressing years. The data also shows that patients within the age brackets of 35 years and above died courtesy of sarcoidosis with those between 65 to 75 years recording the highest rates of 8.5 deaths per 1 million while those between 75 to 84 years reporting nine deaths per 1 million (Liu et al., 2014). Either the rate of deaths among women patients increased by 32% (2.5 to 3.3 per 1 million patients while men morbidity increased by 73.3% (from 1.5 to 2.6 deat.
Spinal Cord Disorders
Definition:-
Spinal Cord Injury(SCI) is an injury to the Spinal Cord that results in temporary or permanent changes in the spinal cords Normal motor sensory or autonomic function.
In most Spinal Cord Injuries, the balance ligaments or disc material pinch the cord, causing it to become bruised or swollen.
1. Incidence
2. Etiology
3. Pathophysiology of SCI
4. Clinical Manifestation
5. Diagnosis
6. Management
7. Nursing Process
8. Nursing Diagnosis
9. Nursing Interventions
Spinal Bifida
Spinal Bifida is a birth defect that occurs when the spinal cord doesn’t form properly.
It is the type of neural tube defect.
The neural tube is the structure in a developing embryo that eventually becomes the body’s Brain, Spinal cord & the tissue that encloses them.
1. types
2. Causes
3. Symptoms
4. Complications
REFERENCES:-
1. Brunner & Siddarth's,
Textbook of Medical-Surgical Nursing,
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
2. Intro
Aetiology
Pathogenisis
Incidence
Diagnosis
Family support
Client’s case
MDT Management
3. An X linked neuromuscular disease characterised by rapidly progressing
muscle weakness and wasting, (WHO, 2013).
Four phases
Early phase (<6 yrs): clumsy, fall frequently, difficulty jumping or
running, enlarged muscles, contractures.
Transitional Phase (ages 6-9): Trunk weakness (Gowers
manouvre), muscle weakness, heart problems, fatigue.
Loss of ambulation (ages 10-14): by 12 yrs most boys use a powered
wheelchair. Scoliosis due to constant sitting and back weakness, UL
weakness make ADL’s difficult (retain use of fingers).
Late stage (15+): life threatening heart and respiratory problems more
prevalent, dyspnea, oedema of the LL’s. Average age of death is 19 yrs in
untreated DMD but due to improvements in clinical care in many centres
the average age of death is the late twenties or beyond, (Bushby et
al, 2005).
4. Sex linked: X-linked genetic recessive disorder
Inherited by the carrier mother/sporadic mutation in the
mothers egg cell (1/3 of cases).
Results in an abnormality in the genetic code for the
protein dystrophin resulting in lack of dystrophin.
(Nowak and Davies, 2004)
5. The dystrophin gene is the largest in the human genome and is
prone to mutation.
60% of dystrophin mutations are large insertions or deletions that
lead to frame shift errors downstream, whereas approximately
40% are point mutations/duplications or small frame shifts/
rearrangements (Hoffman, 2001).
6. Dystrophin links the muscle cells to
the extracellular matrix stabilising
the membrane and protecting the
sarcolemma from the stresses that
develop during muscle contraction.
Mechanically induced damage through
eccentric contractions puts a high
stress on fragile membranes and
provokes micro-lesions that could
eventually lead to loss of calcium
homeostasis, and cell death.
Imbalance between necrotic and
regenerative processes: early phase
of disease.
Later phases the regenerative
capacity of muscle fibers are
exhausted and fibers are gradually
replaced by connective tissue and
adipose tissue.
(Deconinck and Dan, 2007)
7. Incidence: 1 in 3600-6000 (Emery, 1991), (Bushby et al, 2010), Bradley &
Parsons, 1998)
Between 1 February 1993 to 30 June 1994 – DMD incidence was 1 in
12,200 in Northern Ireland (Hughes et al, 1996).
1 in 4200 – The Netherlands (Essen et al, 1992).
1 in 5,600 to 1 in 7,700 DBMD males through 5-24 years in four states in
the U.S.A. 1982-2002. (Ciafoloni et al, 2009)
First symptoms noticed on average at 3.6 years (MDSTARnet, 2007)
8. Mean age of diagnosis in cases without family hx is >4 ½ years (bushby et al, 2005).
Delay in diagnosis of 2 ½ yrs (Bushby et al, 2005), (Parsons et al, 2004)
(Bushby et al, 2010)
9. Family support is NB at this time: provide contact with a named
member of staff and provide details of parental support groups .
http://www.parentprojectmd.org
www.dfsg.org.uk
http://www.mdi.ie/index.html
http://www.informingfamilies.ie/
10. Age: 5 ½ years.
PC: rare Xp21 mutation with Point mutation of exon 7 of the
dystrophin gene resulting in complete absence of dystrophin.
Presentation: (Early ambulatory stage ) - Ambulant, weight – 50th
%, hypertrophy of the calves, +ve Gower's sign, mild lordosis.
Problem List: Poor attention, Speech delay (uses pecs),
?hyperactivity(reported by mother), proximal weakness of lower
and upper limbs and neck flexors, epistaxis, poor balance, gait-
waddle/flat footed, muscle spasm of calves.
PMHX: Initially presented with developmental delays before he
was diagnosed.
11. Corticosteroids: prednisolone 20 mg daily.
Splinting for prevention of contractures at night time.
Check ups with neurologist every 6 months.
Physiotherapy
LTG’s
Improve upper limb strength
Improve lower limb strength
Improve balance
Improve participation in play
STG’s
Increase throwing distance of bean bag from 1 meter to 1 ¼ meters in 3 weeks.
Increase kicking distance of soccer ball while on gym matt from 1 meter to 1 ½ meter in 3 weeks.
Improve one legged stance to 2 seconds in 3 weeks.
Other
Family Support and services
SLT
Psychology
OT
14. Management of muscle extensibility and joint contractures:
stretching and positioning, assistive devices for MSK MGT
(orthoses, standing devices), surgical mgt for LL contractures
(Triple arthrodesis).
Improvement, maintenance and support of muscle strength and
function: Recommendations for physical activity - regular
submaximum (gentle) functional strengthening/activity,
including a combination of swimming-pool exercises and
recreation-based exercises in the community.
Steroid prescription and management
(Fowler et al 2002), (Fowler, 1982), (Bushby et al 2010)
15. Currently best treatment available
Improve Muscle Strength and function
Significantly slow the progression of muscle weakness
Prolong ambulation
Delsy the onset of respiratory and/or cardiac dysfunction
Use with caution as side effects include weight
gain, reduced bone density, hyperactivity, failure to gain
height.
Pednisone/prednisolone – 0.75 mg/kg/day
Deflazacort – 0.9 mg/kg/day
16. 90 % of boys with DMD are likely to develop a clinically significant
scoliosis.
Surgery has shown to be effective in correcting scoliosis and
Success rates are likely to be highest and complication rates
lowest if surgery is performed when the spine is still mobile at a
Cobb angle of 20–40% (Cervellati et al, 2004) .
Spinal bracing for those unable for surgery.
Triple arthrodesis may be required
Bone health: Fractures (long bone and
vertebral)Osteopenia, Osteoporosis Kyphoscoliosis, Bone
pain, Reduced QOL – DEXA scans, serum/urine tests, spine
readiograph – Vit D, Calcium, Biphosphonates.
17. (Eagle et al, 2007) Kaplan–Meier survival plot to show the impact of spinal surgery and
ventilation on survival. Survival curves are significantly different p = 0.0001.
18. Death is due to cardiac dysfunction in 10% of cases (Gulatie et
al, 2005).
Dilated cardiomyopathy: A condition in which the heart becomes
weakened and enlarged. As a result, the heart cannot pump
enough blood to the rest of the body.
Death due to cardiomyopathy is expected to rise now that life
expectancy increases, (Bushby et al, 2003).
It is estimated that 20–30% of DMD boys have left ventricular
impairment on echocardiography by age 10 years (Bushby et al,
2005).
Cardiac mgt should be implemented at diagnosis as clinical
symptoms appear later than initial cardiac dysfunction,
echocardiogram & electrocardioram – at 6 yrs, every 2 yrs up to
age 10 and annually after 10 yrs +.
ACE and beta blockers
(American academy of Paediatrics, 2005)
20. Panel 1: Respiratory interventions indicated in patients with Step 3: nocturnal ventilation
Duchenne Nocturnal ventilation† is indicated in patients who have
muscular dystrophy any of the following:
Step 1: volume recruitment/deep lung infl ation technique • Signs or symptoms of hypoventilation (patients with FVC
Volume recruitment/deep lung infl ation technique (by self-infl ating <30% predicted are at
manual ventilation bag especially high risk)
or mechanical insuffl ation–exsuffl ation) when FVC <40% predicted • A baseline SpO2
Step 2: manual and mechanically assisted cough tech <95% and/or blood or end-tidal CO2
• Respiratory infection present and baseline peak cough fl ow <270 >45 mm Hg while awake
L/min* • An apnoea–hypopnoea index >10 per hour on
• Baseline peak cough fl ow <160 L/min or maximum expiratory polysomnography or four or more
pressure <40 cm water episodes of SpO2
• Baseline FVC <40% predicted or <1·25 L in older teenager/adult <92% or drops in SpO2
of at least 4% per hour of sleep
Optimally, use of lung volume recruitment and assisted
cough techniques should always
precede initiation of non-invasive ventilation
Step 4: daytime ventilation Step 5: tracheostomy
In patients already using nocturnally assisted ventilation, daytime Indications for tracheostomy include:
ventilation‡ is • Patient and clinician preference§
indicated for: • Patient cannot successfully use non-invasive ventilation
• Self extension of nocturnal ventilation into waking hours • Inability of the local medical infrastructure to support
• Abnormal deglutition due to dyspnoea, which is relieved by non-invasive ventilation
ventilatory assistance • Three failures to achieve extubation during critical illness
• Inability to speak a full sentence without breathlessness, and/or despite optimum use of
• Symptoms of hypoventilation with baseline SpO2 non-invasive ventilation and mechanically assisted cough
<95% and/or blood or end-tidal CO2 • The failure of non-invasive methods of cough assistance
>45 mm Hg while awake to prevent aspiration of
Continuous non-invasive assisted ventilation (with mechanically secretions into the lung and drops in oxygen saturation
assisted cough) can below 95% or the patient’s
facilitate endotracheal extubation for patients who were intubated baseline, necessitating frequent direct tracheal suctioning
during acute via tracheostomy
illness or during anaesthesia, followed by weaning to nocturnal non-
invasive assisted
ventilation, if applicable
22. Nutritionist/dietician: to guide the patient to maintain good
nutritional status to prevent both under nutrition/malnutrition
and being overweight/obese, and to provide a well-
balanced, nutrient-complete diet.
SLT: To monitor and treat swallowing problems, to prevent
aspiration and weight loss, and to assess and treat delayed
speech and language problems.
Clinical Nurse specialist: Family Support and Services
OT: Continue previous measures Provision of appropriate
wheelchair and seating, and aids and adaptations to allow
maximum independence in ADL, function, and participation.
23. Centers for Disease Control and Prevention (CDC).Prevalence of Duchenne/Becker muscular
dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Mortal Wkly Rep. 2009 Oct
16;58(40):1119-22.
Deconinck, N., & Dan, B. (2007). Pathophysiology of duchenne muscular dystrophy: current
hypotheses. Pediatric neurology, 36(1), 1-7.
Hoffman EP, Dressman D (2001) Molecular pathophysiology and targeted therapeutics for muscular
dystrophy. Trends Pharmacol Sci 22: 465–470
Nowak, K. J., & Davies, K. E. (2004). Duchenne muscular dystrophy and dystrophin: pathogenesis
and opportunities for treatment. EMBO reports, 5(9), 872-876.
Ouyang L, Grosse SD, Kenneson A. Health Care Utilization and Expenditures for Children and Young
Adults With Muscular Dystrophy in a Privately Insured Population. J Child Neurol. 2008 Aug;23
(8):883-8.
Hughes, M. I., Hicks, E. M., Nevin, N. C., & Patterson, V. H. (1996). The prevalence of inherited
neuromuscular disease in Northern Ireland.Neuromuscular Disorders, 6(1), 69-73.
24. Gulati, S., Saxena, A., Kumar, V., & Kalra, V. (2005). Duchenne muscular dystrophy: prevalence and
patterns of cardiac involvement. Indian journal of pediatrics, 72(5), 389-393.
Bushby, K., Bourke, J., Bullock, R., Eagle, M., Gibson, M., & Quinby, J. (2005). The
multidisciplinary management of Duchenne muscular dystrophy.Current Paediatrics, 15(4), 292-
300.
Chung, B., Wong, V., & Ip, P. (2003). Prevalence of neuromuscular diseases in Chinese children: a
study in southern China. Journal of child neurology, 18(3), 217-219
Manzur AY, Kuntzer T, Pike M, Swan A, Glucocorticoid corticosteroids for Duchenne muscular
dystrophy (Cochrane review). The Cochrane Library, Chichester UK, Wiley, 2004.
Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International
Workshop: Treatment of Duchenne muscular dystrophy; defining the gold standards of management
in the use of corticosteroids. 2–4 April 2004, Naarden, The Netherlands. Neuromuscul Disord
2004;14(8–9):526–34.
Moxley III RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of
Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of
Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64(1):13–20.
Cervellati S, Bettini N, Moscato M, Gusella A, Dema E, Maresi R. Surgical treatment of spinal
deformities in Duchenne muscular dystrophy: a long term follow-up study. Eur Spine J
2004;13(5):441–8.
25. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular
dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;170(4):456–65.
Eagle, M., Bourke, J., Bullock, R., Gibson, M., Mehta, J., Giddings, D., ... & Bushby, K. (2007).
Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal
ventilation in improving survival.Neuromuscular disorders: NMD, 17(6), 470.
Bushby KMD, Muntoni F, Bourke JP. The management of cardiac complications in muscular
dystrophy and myotonic dystrophy. Proceedings of 107th ENMC Workshop. Neuromuscul Disord
2003;13:166–72.
American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health
supervision for in dividuals aff ected by Duchenne or Becker muscular dystrophy. Pediatrics 2005;
116: 1569–73
Bushby, K., Bourke, J., Bullock, R., Eagle, M., Gibson, M., & Quinby, J. (2005). The
multidisciplinary management of Duchenne muscular dystrophy.Current Paediatrics, 15(4), 292-
300.
Parsons, E. P., Clarke, A. J., & Bradley, D. M. (2004). Developmental progress in Duchenne
muscular dystrophy: lessons for earlier detection. European journal of paediatric neurology: EJPN:
official journal of the European Paediatric Neurology Society, 8(3), 145.
Essen, A. J., Busch, H. F. M., Meerman, G. J., & Kate, L. P. (1992). Birth and population prevalence
of Duchenne muscular dystrophy in The Netherlands.Human genetics, 88(3), 258-266.
26. Drousiotou A, Ioannou P, Georgiou T, et al. Neonatal screening for Duchenne muscular
dystrophy: a novel semiquantitative application of the bioluminescence test for creatine
kinase in a pilot national program in Cyprus. Genet Test 1998; 2: 55–60.
Bradley D, Parsons E. Newborn screening for Duchenne muscular dystrophy. Semin
Neonatol 1998; 3: 27–34.
Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey
Neuromuscul Disord 1991; 1: 19–29 .
Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, et al. Delayed
diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy
Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 2009
Sept;155(3):380-5.
Fowler WM Jr. Role of physical activity and exercise training in neuromuscular
diseases. Am J Phys Med Rehabil 2002; 81 (suppl): S187–95.
Fowler WM Jr. Rehabilitation management of muscular dystrophy and related
disorders: II. Comprehensive care. Arch Phys Med Rehabil 1982; 63: 322–28
27. (Parsons et al, 2004) Milestone Late/never Median age
achieved (range
(%) case achieved)
numbers (months)
Walking alone (89%) 16/18 16 (13–27)
Sitting alone (67%) 12/18 8 (5–16)
Meaningful (53%) 9/17 29 (20–43)
sentences
Single words (47%) 8/17 13 (9–24)